Beneficial effects of botulinum toxin type a in trigeminal neuralgia

Arquivos de Neuro-Psiquiatria

Volumn 66, Issue 3 A, 2008, Pages 500-503

  Zúñiga, Carlos ^a,b   Díaz, Sergio ^a   Piedimonte, Fabián ^a   Micheli, Federico ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b NONE   (Mexico)

Author keywords

Botulinum toxin; Facial pain; Trigeminal neuralgia

Indexed keywords

BOTULINUM TOXIN A; CARBAMAZEPINE; OXCARBAZEPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; MALE; MASSETER MUSCLE; PAIN ASSESSMENT; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; BOTULINUM TOXINS, TYPE A; FACIAL PAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 52949097981     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2008000400012     Document Type: Article

References (18)

1. Yoshimasu F, Kurland LT, Elveback LR. Tic douloureaux in Rochester, Minnesota, 1945-1969. Neurology 1972;22:952-956.
2. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-281.
3. Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery 1994;35:299-303.
4. Bowsher D. Trigeminal neuralgia: an anatomically oriented review. Clin Anat 1997;10:409-415.
5. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 2002;25:260-262.
6. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005;65:1306-1308.
7. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3:21-27.
8. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003;43:853-860.
9. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-450.
10. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofacial pain syndrome. Pain 1994;59:65-69.
11. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18(Suppl 6):S177-S181.
12. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 2002;18(Suppl 6):S147-S154.
13. Christiansen J, Bruun E, Skjoldbye B, Hagen K. Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum 2001;44:661-665.
14. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995;10:333-336.
15. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain 2001;124:2347-2360.
16. Burchiel KJ, Slavin KV. On the natural history of trigeminal neuralgia. Neurosurgery 2000;46:152-155.
17. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg 2004;30:452-455.
18. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251(Suppl 1):S1-S7.